MedPath

Study on the clinical significance of Saireito in patients with hypertensive nephropathy

Not Applicable
Conditions
hypertensive nephropathy
Registration Number
JPRN-UMIN000011825
Lead Sponsor
ational Center for Global Health and Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

* in pregnancy and lactating * contraindicative or impossible to use for some reason for Saireito * treated with oral corticosteroids or immunosuppressant therapy * interstitial pneumonitis * definite diabetes mellitus * marked renal impairment (eGFR = or < 30 ml/min) * primary renal disease * secondary renal disease * serious CHF * serious arrythmia * within 6 months after AMI * within 6 months after cerebrovascular disease

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Decrease in microalbuminuria
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath